Aytu BioPharma Inc is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. It has single operating segment. Its product portfolio includes EXXUA, ADHD Portfolio, Pediatric Portfolio, and Other. Majority of revenue comes from ADHD Portfolio. It has presence in United States.
Last trade$2.66
Day change+$0.835 (+45.88%)
Day range$2.53 – $2.67
Volume4,006,841
Market cap$20M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$19.78M
Price / earnings
—
Price / book
0.56×
Price / sales
0.34×
EV / sales
0.18×
EV / EBITDA
-2.39×
Profitability
Earnings per share
-$1.31
Return on assets
-13.57%
Return on equity
-40.4%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.48×
Current ratio
1.13×
Quick ratio
1×
Cash ratio
0.48×
Cash flow
Price / cash flow
6.03×
Price / free cash flow
6.08×
Free cash flow
$3.25M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AYTU, quarterly periods
Line item
Q4 FY2026 Jun 30, 2026
Q3 FY2026 Mar 31, 2026
Q2 FY2026 Dec 31, 2025
Q1 FY2026 Sep 30, 2025
Q4 FY2025 Jun 30, 2025
Q3 FY2025 Mar 31, 2025
Q2 FY2025 Dec 31, 2024
Q1 FY2025 Sep 30, 2024
Revenue
$16.11M
$12.41M
$15.17M
$13.89M
$15.14M
$18.45M
$16.22M
$16.57M
Cost of revenue
$5.7M
$4.81M
$5.54M
$4.7M
$4.88M
$5.65M
$5.44M
$4.59M
Gross profit
$10.41M
$7.6M
$9.62M
$9.19M
$10.25M
$12.81M
$10.79M
$11.99M
Selling, general and administrative
$10.43M
$10.9M
$11.07M
$10.25M
$8.48M
$9.3M
$9.72M
$10.78M
Research and development
$0
$0
$0
$0
$216K
$162K
$522K
$426K
Total operating expenses
$11.19M
$11.66M
$11.59M
$10.69M
$17.88M
$10.39M
$12.48M
$12.92M
Operating income
-$777K
-$4.06M
-$1.97M
-$1.5M
-$7.62M
$2.42M
-$1.7M
-$930K
Interest expense
-$383K
-$436K
-$560K
-$516K
-$730K
-$900K
-$1.08M
-$994K
Income before taxes
-$4K
-$5.61M
-$10.58M
$1.97M
-$19.44M
$3.82M
$382K
$1.5M
Income taxes
$11K
$10K
$0
$0
$437K
-$122K
-$283K
$405K
Net income
-$15K
-$5.62M
-$10.58M
$1.97M
-$19.82M
$3.99M
$788K
$1.47M
Net income attributable to common shareholders
-$15K
-$5.62M
-$10.58M
$1.97M
-$19.82M
$3.99M
$788K
$1.47M
EBITDA
$344K
-$2.94M
-$1.09M
-$701K
$2.1M
$3.71M
$914K
$1.19M
Basic earnings per share
$0.00
-$0.53
-$1.05
$0.21
-$2.92
$0.65
$0.13
$0.24
Diluted earnings per share
$0.00
-$0.53
-$1.05
-$0.08
—
$0.21
-$0.26
-$0.15
Recent news
Company coverage with links to the original publishers.
Aytu BioPharma reported a quarterly loss of $0.2 per share, missing consensus estimates of $0.1 loss, representing a -100% earnings surprise. The company posted revenues of $14.84 million, slightly beating estimates. With unfavorable estimate revisions, the stock received a Zacks Rank #5 (Strong Sell) rating and has declined 31.5% year-to-date versus the S&P 500's 10.5% gain.
Cerenome (CNSY) reported a quarterly loss of $1.14 per share, missing the consensus estimate of $0.98 loss by 16.33%. While revenues of $0.72 million beat estimates by 44.40%, they declined significantly from $1.4 million year-ago. The stock has plummeted 94% since the beginning of 2026 versus the S&P 500's 10.9% gain. Zacks assigned the stock a Hold rating (Rank #3) with mixed estimate revisions ahead.
Zealand Pharma A/S reported a quarterly loss of $0.12 per share, beating consensus estimates of $1.33 loss by 90.98%, but revenues of $0.62 million missed estimates by 97.57%. The stock has declined 48.7% year-to-date versus the S&P 500's 11.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
CytomX Therapeutics reported a quarterly loss of $0.09 per share matching consensus estimates, but revenues of $1.69 million missed expectations by 59.68%, down significantly from $5.96 million year-ago. The stock has declined 44.8% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions. The Medical - Biomedical and Genetics industry ranks in the top 45% of sectors.
Elite Pharmaceuticals (ELTP) and Aytu BioPharma (AYTU) are two pharmaceutical companies with CNS and ADHD market exposure, but with different strategies. ELTP focuses on generic pharmaceuticals with an expanding pipeline and strong financial position, while AYTU emphasizes branded medicines centered on its EXXUA growth catalyst. Despite both trading below sector valuations, ELTP is recommended as the better buy due to its broader commercial base, lower execution risk, and improving operating momentum, while AYTU presents a higher-risk turnaround story dependent on EXXUA's success.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.